Hims & Hers Health NYSE:HIMS Stock Report

Hims & Hers Health: Promising Return Profile

Hims is a stock which the market has punished beyond what is rational. The company is progressing nicely towards profitability and the share price should begin to creep up. The company's value proposition will lead to a solid moat. The company's effort to vertically integrate will expedite this process. I believe the fair share price is around $18, which represents a 2-3x return on an investor's money. There are numerous risks involved, included, but not limited to: losses, rising interest rates, larger competitors, government regulation, and poor retention rates. Introduction Hims & Hers Health (HIMS) is a telehealth company which focuses on providing high-quality and easy access healthcare, primarily for stigmatized disorders. The company’s target demographics are millennials and Gen Z. The company is in its fifth year of operation and went public via SPAC in 2021. Since then, the share price has fallen from $25 to around $5 today, which represents an 80% decline. Why has the Share Price Fallen? There are a few aggregate-based explanations for why Hims has fallen: All major indices have significantly declined. Rates have increased, which lowers the future value of growth stocks the most. Investors are simply wrong and too negative in their forecast of the company’s future earnings. My rebuttal to the three reasons is as follows: It is a market of stocks, not a stock market. If a company’s earnings increase, its stock price will as well. The overall market being viscous might delay share appreciation but cannot do so forever. Ultimately, Hims stock price will reflect its true potential (as long as the company continues to execute). A company’s value is calculated by discounting all its future cash flows. The further into the future a company’s projected cash flows are, the more of an impact interest rates have mathematically. Hims should be profitable sooner rather than later if the company continues on its trajectory. As such, its future cash flows are closer than investors perceive, and the stock price will greatly benefit once they account for this realization. Investors who believe the company will not be profitable are wrong. The fact that Hims could be profitable today if they simply cut back on their marketing expense reveals the company can already be thought of as profitable (for the sake of evaluation). As the increased marketing spend turns into higher sales (and retention rates), the company’s top line will seep into its bottom line. Hims’ Moat I often hear investors complain Hims has no moat and thus will get gobbled up by larger competitors such as CVS (CVS) or Amazon (AMZN). What critics do not understand is moat comes second – the value proposition comes first. Investors who ask where is the moat are putting the “cart before the horse.” One can claim any company had no moat at first. What moat did NIKE (NKE) had at first? Anyone could create an athletic clothing brand. After all, adidas ([[ADDYY]], [[ADDDF]]) had a fifteen-year head start on Nike. I am sure skeptic investors at the time said Nike has no moat and Adidas can out-compete them. The value proposition is what matters. If Hims provides patients with high quality and convenient healthcare at the lowest price, it will produce a profit. As it produces a profit, the company will expand its capabilities and infrastructure while becoming more efficient. This is what people refer to when they mention 'moat' – it is the competitive advantages a business possesses that are derived by its capabilities, infrastructure, and efficiencies. In other words, value proposition creates the moat. It is illogical and non-chronological for a moat to create value. Hims’ Vertical Integration One of the keys to Hims’ value proposition and moat is the company’s ability to vertically integrate. Management has demonstrated they recognize this key and are progressing towards this goal. Mobile App The company’s primary touchpoint is its new mobile app, which allows patients to get a medical consultation directly from the app within a few taps. These consultations have grown at a CAGR of almost 130% from 2018-2021. Medical Consultations Since Launch (Hims Investor Presentation) Branded Products and Fulfillment Centers to Ship Them The company makes a large chunk of sales off its own brand name products and custom formularies rather than solely relying on third-party drug manufacturers. The company has two internal fulfillment centers, one in Ohio and one in Arizona, which fill over 50% of orders. Fulfillment Centers (Hims Investor Presentation) Although these are beginner steps toward vertical integration, it demonstrates the company is heading in the right directions and understands the importance of this strategy. Valuation I believe the company is worth $18.20 per share, which represents more than threefold increase from current levels. Revenue Growth I believe 2022 revenue growth will be $544MM. This represents a 100% increase over 2021 revenue of $272MM. Many readers have commented that this is too high and I disagree. Quarterly Revenue Growth (Hims Investor Presentation) From the graph above, we can see the company has increased revenue by 16.6% CAGR per quarter from Q1 2019 to Q1 2022. This was achieved without the main catalyst of the mobile app, not to mention the absence of thousands of new retail touchpoints. Simply extrapolating each quarter this year at a 16.6% growth rate leaves us with these forecasts: Q1 2022: $101MM Q2 2022: $118MM Q3 2022: $137MM Q4 2022: $160MM Adding up my forecasted revenue equals $516MM. I think the extra “umph” to get to $544MM will come from the mobile app; I think investors are severely underestimating the revenue-generating power of the app. Discounted Cash Flow Model Before I dive into the specifics, I want to point out valuation is an art, not a science. Two investors separately analyzing the same stock will almost certainly come up with two different valuations. Discounted Cash Flow Model (Author) COGS Cost of goods sold and gross margins are flip sides of the same coin. Hims' gross margin for 2021 was 75%. For 2022, I predict a 73% gross margin rate. From there, I gradually lowered it over the following years. Hims has expanded into numerous retail channels (Amazon, CVS, Walmart (WMT), etc.) and sales from those channels carry lower margins. Therefore, it is wise to factor this in the forecast. SGA The company's SGA expense as a percentage of sales was 117% in 2021. I assumed this would stay the same in 2022 and then would gradually get better since overall sales would outpace the spending at this level. Taxes, Net CA, CAPX